{"title":"Field Study on the Assessment of Antimalarial Drug Quality Using Minilab Kit\nin India","authors":"Saba Noor, Supriya Sharma, Taruna Arora","doi":"10.2174/0102506882296927240628080941","DOIUrl":null,"url":null,"abstract":"\n\nA lack of proper anti-malarial medication use can lead to drug resistance, failed therapy, and even death. It is unclear how widespread the use of\nfake anti-malarial medications is in India. Better malaria treatment and the execution of regulatory initiatives to improve anti-malarial drug quality\nnecessitate regional research into the quality of available anti-malarial pharmaceuticals. This study aimed to look into the quality of anti-malarial\ndrugs in regions of India where malaria is common. Conclusions about the prevalence of substandard anti-malarial medications in Indian\ncommunities can be drawn from the findings.\n\n\n\nSamples of anti-malarial pills were bought from stores in five different Indian areas. One hundred and fifty anti-malarial drug samples were\ngathered. Using a GPHF minilab lab kit, the quality of the following samples was determined: chloroquine (n=50), artemether lumefantrine (n=50),\nartesunate sulphadoxine-pyrimethamine (n=14), and primaquine (n=31).\n\n\n\nThis research confirmed that 98% of the tablets disintegrated properly in a minilab disintegration test. As a result, when compared to both the full\nset of standards and 80% of the samples, 99% of the samples passed the preliminary qualitative TLC test. Only 4% of samples (those with\ninsufficient amounts of the active medicinal component) failed the quantitative HPLC test.\n\n\n\nAnti-malarial medicine counterfeiting has been found to be quite uncommon in India compared to other countries. However, further research is\nneeded, such as post-marketing surveillance, to ensure that effective anti-malarials are distributed to the public.\n","PeriodicalId":110816,"journal":{"name":"New Emirates Medical Journal","volume":"12 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Emirates Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0102506882296927240628080941","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A lack of proper anti-malarial medication use can lead to drug resistance, failed therapy, and even death. It is unclear how widespread the use of
fake anti-malarial medications is in India. Better malaria treatment and the execution of regulatory initiatives to improve anti-malarial drug quality
necessitate regional research into the quality of available anti-malarial pharmaceuticals. This study aimed to look into the quality of anti-malarial
drugs in regions of India where malaria is common. Conclusions about the prevalence of substandard anti-malarial medications in Indian
communities can be drawn from the findings.
Samples of anti-malarial pills were bought from stores in five different Indian areas. One hundred and fifty anti-malarial drug samples were
gathered. Using a GPHF minilab lab kit, the quality of the following samples was determined: chloroquine (n=50), artemether lumefantrine (n=50),
artesunate sulphadoxine-pyrimethamine (n=14), and primaquine (n=31).
This research confirmed that 98% of the tablets disintegrated properly in a minilab disintegration test. As a result, when compared to both the full
set of standards and 80% of the samples, 99% of the samples passed the preliminary qualitative TLC test. Only 4% of samples (those with
insufficient amounts of the active medicinal component) failed the quantitative HPLC test.
Anti-malarial medicine counterfeiting has been found to be quite uncommon in India compared to other countries. However, further research is
needed, such as post-marketing surveillance, to ensure that effective anti-malarials are distributed to the public.